Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a significant increase in short interest in April. As of April 15th, there was short interest totalling 62,800 shares, an increase of 307.8% from the March 31st total of 15,400 shares. Based on an average daily volume of 287,600 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the shares of the stock are sold short.

Oncotelic Therapeutics Trading Up 2.6 %

OTLC opened at $0.06 on Tuesday. The stock has a 50-day moving average of $0.05 and a 200 day moving average of $0.04. The company has a current ratio of 0.01, a quick ratio of 0.01 and a debt-to-equity ratio of 0.28. Oncotelic Therapeutics has a 12 month low of $0.02 and a 12 month high of $0.07. The firm has a market cap of $24.23 million, a P/E ratio of -5.95 and a beta of -0.69.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.